| K-CAB Tab (tegoprazan) / RaQualia, Sebela |
NCT05586113: The Efficacy of 10-day or 14-day Course of Bismuth-containing Quadruple Therapy:A Randomized Clinical Trial |
|
|
| Not yet recruiting | 4 | 398 | RoW | 10-day Tegoprazan bismuth-containing quadruple therapy | Shandong University, Linyi People's Hospital, Weifang Medical University | Helicobacter Pylori Infection | 10/23 | 12/23 | | |
NCT05438550: 14-day Double Therapy Versus Bismuth Quadruple Therapy in First-line Treatment of Helicobacter Pylori Infection |
|
|
| Not yet recruiting | 4 | 258 | RoW | 14-day high-dose Tegoprazan Dual Therapy (HDDT), Tegoprazan (Rosin Pharmaceutical Group Co. LTD.) 50mg bid, Amoxicillin (Amoxicillin, United Laboratories Co. LTD) 750mg qid | Shandong University | Helicobacter Pylori Infection | 12/23 | 12/23 | | |
NCT06318104: Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Tegoprazan vs Esomeprazole |
|
|
| Not yet recruiting | 4 | 160 | NA | Tegoprazan, P-CAB, Esomeprazole 40mg, PPI | Hospital General de México Dr. Eduardo Liceaga | Helicobacter Pylori Infection | 11/24 | 02/25 | | |
| Not yet recruiting | 4 | 300 | | Amoxicillin (1000mg each time, three times a day) + tegoprazan (50mg each time, once a day) for 2 weeks ;Amoxicillin (1000mg each time, three times a day) + tegoprazan(50mg each time, twice a day) for 2 weeks ;Amoxicillin (1000mg twice daily)+ clarithromycin (500mg twice daily)+ bismuth (220mg twice daily)+ esomeprazole (20mg twice daily) for 2 weeks | Fujian Provincial Hospital; Fujian Provincial Hospital, Bethune Public Welfare Foundation | Helicobacter pylori infection | | | | |
ChiCTR2200066010: Efficacy and safety of Tegoprazan-amoxicillin dual therapy for Helicobacter pylori rescue therapy |
|
|
| Not yet recruiting | 4 | 280 | | 14-day dual regimen with Tegoprazan (Tegoprazan 50 mg bid + amoxicillin 1g TID) ;14-day bismuth containing quadruple therapy (Esomeprazole 20 mg bid + amoxicillin 1 g bid + Furazolidone 100 mg bid + bismuth potassium citrate 220 mg bid) | The Eighth Affiliated Hospital, Sun Yet-san University; The Eighth Affiliated Hospital, Sun Yet-san University, Self-funding | helicobacter pylori | | | | |
| Not yet recruiting | 4 | | | | The Third People's Hospital of Chengdu; The Third People's Hospital of Chengdu, Bethune Public Welfare Foundation | Gastro-sophageal Reflux Disease | | | | |
TATH-1, NCT05647278: A RCT of the Efficacy of Tegoprazan 50mg QD in the Treatment of Helicobacter Pylori Infection ( ) |
|
|
| Active, not recruiting | 4 | 100 | RoW | Tegoprazan, Esomeprazole | Zhang Xiaofeng,MD | Vonoprazan, Helicobacter Pylori Infection, Proton Pump Inhibitor | 12/24 | 12/24 | | |
NCT05701540: A Study to Evaluate the Efficacy and Safety of Tegoprazan in GERD Patients With Nighttime Heartburn |
|
|
| Recruiting | 4 | 338 | RoW | Tegoprazan, Esomeprazole | HK inno.N Corporation | Gastroesophageal Reflux Disease | 12/24 | 12/24 | | |
ChiCTR2300070015: Study of the role and mechanism of tegoprazan on functional dyspepsia |
|
|
| Not yet recruiting | 4 | 285 | | tegoprazan ;placebo | West China Hospital, Sichuan University; West China Hospital, Sichuan University, crosswise tasks | functional dyspepsia | | | | |
PROTECT-HBR, NCT04416581: Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy |
|
|
| Recruiting | 4 | 3100 | RoW | PPI, P-CAB 50 | Duk-Woo Park, MD | Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction | 09/26 | 12/27 | | |
NCT05871398: The Efficacy of Potassium-competitive Acid Blocker in Patients With Laryngopharyngeal Reflux Disease |
|
|
| Completed | 3 | 36 | RoW | Tegoprazan, Placebo | Pusan National University Hospital | Laryngopharyngeal Reflux Disease | 12/21 | 02/23 | | |
NCT05010954: Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer |
|
|
| Completed | 3 | 400 | RoW | LXI-15028 50mg group, Lansoprazole 30mg group | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Duodenal Ulcer | 09/22 | 09/22 | | |
NCT05587322: A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease |
|
|
| Active, not recruiting | 3 | 800 | US | BLI5100, Placebo | Braintree Laboratories | Non-erosive Reflux Disease | 01/24 | 05/24 | | |
NCT05577468: Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori |
|
|
| Completed | 3 | 561 | RoW | Tegoprazan | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Helicobacter Pylori Infection | 09/23 | 09/23 | | |
NCT05890001: A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease |
|
|
| Enrolling by invitation | 3 | 400 | US | BLI5100 | Braintree Laboratories | Non-erosive Reflux Disease, Erosive Esophagitis | 03/24 | 09/24 | | |
NCT04840550: Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDs |
|
|
| Recruiting | 3 | 390 | RoW | Lansoprazole 15 mg, Tegoprazan 25 mg | HK inno.N Corporation | Preventive Peptic Ulcer | 06/24 | 07/24 | | |
NCT05587309: A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis |
|
|
| Recruiting | 3 | 1250 | US | BLI5100, PPI Control | Braintree Laboratories | Erosive Esophagitis | 06/24 | 12/24 | | |
NCT05933031: Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients |
|
|
| Recruiting | 2 | 381 | RoW | Tegoprazan 50 mg Triple Therapy, Tegoprazan 100 mg Triple Therapy, Lansoprazole Triple Therapy | HK inno.N Corporation | Helicobacter Pylori Infection | 12/24 | 12/24 | | |
NCT04587011: A Study to Explore Pharmacokinetics/Pharmacodynamics and Safety of Tegoprazan BID Dosing in Healthy Subjects |
|
|
| Recruiting | 1 | 40 | RoW | Tegoprazan dose A or placebo, Tegoprazan dose B or placebo, Tegoprazan dose C or placebo, Tegoprazan dose D or placebo | HK inno.N Corporation | Healthy | 03/21 | 06/21 | | |
NCT05353010: A Study to Evaluate Effect of IN-A001 on Pharmacokinetics of Tacrolimus in Healthy Volunteers |
|
|
| Not yet recruiting | 1 | 12 | RoW | Tacrolimus, prograf, IN-A001(Tegoprazan), K-CAB, IN-A001(Tegoprazan) + Tacrolimus, IN-A001: K-CAB, Tacrolimus: Prograf | HK inno.N Corporation | Healthy | 07/22 | 11/22 | | |
NCT05883306: Mass Balance and Biotransformation Study of [14C]LXI-15028 in Humans |
|
|
| Completed | 1 | 6 | RoW | [14C]LXI-15028 | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Healthy Subjects, Pharmacokinetics of 14C-labeled of LXI-15028 | 07/22 | 12/22 | | |
NCT05915871: Drug Interaction Study Between Tegoprazan, Bismuth, Amoxicillin and Clarithromycin |
|
|
| Completed | 1 | 22 | RoW | Tegoprazan, Bismuth, Amoxicilli, Clarithromycin | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Healthy | 04/23 | 04/23 | | |
NCT05723510: PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers |
|
|
| Completed | 1 | 87 | RoW | Tegoprazan 50mg, K-CAB Tab. 50 mg, Edoxaban 60mg, Lixiana Tab. 60mg, Apixaban 5mg, Eliquis Tab. 5 mg, Rivaroxaban 20mg, Xarelto Tab. 20 mg | HK inno.N Corporation | Healthy | 07/23 | 07/23 | | |
NCT04494269: A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls |
|
|
| Recruiting | 1 | 28 | RoW | Tegoprazan 50mg, K-CAB | HK inno.N Corporation | Hepatic Impairment, Healthy | 06/23 | 12/23 | | |
NCT06164834: Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 48 | RoW | Clopidogrel 75 mg, Plavix, Tegoprazan 25 mg, K-CAB, Esomeprazole 20mg, Nexium | HK inno.N Corporation | Healthy | 11/24 | 11/24 | | |
NCT06332638: PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects |
|
|
| Enrolling by invitation | 1 | 36 | RoW | Tegoprazan 12.5mg, Tegoprazan Tab. 12.5mg, Tegoprazan 25mg, K-CAB Tab. 25mg, Famotidine 20mg, Gaster Tab. 20 mg Dong-A | HK inno.N Corporation | Healthy | 07/24 | 07/24 | | |
| Recruiting | N/A | 400 | RoW | Tegoprazan-containing sequential H. pylori eradication therapy, Esomeprazole-containing sequential H. pylori eradication therapy | Seoul National University Bundang Hospital | Helicobacter Pylori Infection | 12/24 | 12/24 | | |
NCT04674774: Efficacy of Tegoprazan Based Bismuth Quadruple Therapy for Helicobacter Pylori Infection |
|
|
| Active, not recruiting | N/A | 217 | RoW | Tegoprazan, Lansoprazole | Incheon St.Mary's Hospital | Helicobacter Pylori Infection | 02/22 | 03/22 | | |
NCT05870683: Comparison of Two Dual Therapies in the First-line Treatment of Helicobacter Pylori Infection （SHARE2301） |
|
|
| Recruiting | N/A | 368 | RoW | Tegoprazan, Amoxicillin, Esomeprazole | Yanqing Li, Linyi People's Hospital, Weifang Medical University, Zhengzhou Central Hospital, Yuncheng Traditional Chinese Medicine Hospital, The Affiliated Hospital of Qingdao University, The People's Hospital of Jimo, The Second Affiliated Hospital of Shandong University of traditional Chinese Medicine | Helicobacter Pylori Infection | 10/23 | 12/23 | | |
NCT06340334: Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study |
|
|
| Not yet recruiting | N/A | 600 | NA | Tegoprazan-amoxicillin dual therapy, Furazolidone-based Bismuth Quadruple Therapy | Nanjing First Hospital, Nanjing Medical University | Helicobacter Pylori Infection, Tegoprazan, Furazolidone | 12/24 | 12/24 | | |
NCT06431737: Comparison of Twice- and Four-times-daily Amoxicillin Administration in 2-week Tegoprazan-based H. Pylori Eradication |
|
|
| Recruiting | N/A | 100 | RoW | Amoxicillin | Soonchunhyang University Hospital | H.Pylori Infection | 08/24 | 12/24 | | |
NCT05997433: Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori（SHARE2302) |
|
|
| Recruiting | N/A | 254 | RoW | 7days bismuth quadruple, Amoxicillin, Tetracycline, Bismuth, Tegoprazan, 14 days bismuth quadruple | Shandong University, Zibo Maternal and Child Health Hospital, Zaozhuang Municipal Hospital, Binzhou Maternal and Child Health Hospital, Jinxiang County People's Hospital, Linyi Yizhou Hospital, Yantai Penglai Traditional Chinese Medicine Hospital, The Second Affiliated Hospital of Shandong University of traditional Chinese Medicine | Helicobacter Pylori Infection | 08/24 | 08/24 | | |
NCT05620589: The Effect of Time Intervals for Rescue Treatment on Eradication Effect of Helicobacter Pylori Infection |
|
|
| Not yet recruiting | N/A | 626 | RoW | Amoxicillin + Tetracycline + Bismuth + Esomeprazole, Amoxicillin + Tetracycline + Bismuth + Vonoprazan, Amoxicillin + Tetracycline + Bismuth + Tegoprazan | Shandong University, Peking University Care Luzhong Hospital, Yuncheng Hospital of Traditional Chinese Medicine, Taierzhuang District People's Hospital, The First Affiliated Hospital of Zhengzhou University, Zibo Central Hospital | Helicobacter Pylori Infection | 12/24 | 12/24 | | |
| Pizensy (lactitol) / Sebela |
| No trials found |
